chr5-149980428-C-T

Variant summary

Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PP5_Very_Strong

The NM_000112.4(SLC26A2):​c.835C>T​(p.Arg279Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00142 in 1,614,060 control chromosomes in the GnomAD database, including 5 homozygotes. Variant has been reported in ClinVar as Likely pathogenic (★★).

Frequency

Genomes: 𝑓 0.0011 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0015 ( 5 hom. )

Consequence

SLC26A2
NM_000112.4 missense

Scores

13
5
1

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:37O:1

Conservation

PhyloP100: 3.22
Variant links:
Genes affected
SLC26A2 (HGNC:10994): (solute carrier family 26 member 2) The diastrophic dysplasia sulfate transporter is a transmembrane glycoprotein implicated in the pathogenesis of several human chondrodysplasias. It apparently is critical in cartilage for sulfation of proteoglycans and matrix organization. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_pathogenic. Variant got 8 ACMG points.

PP5
Variant 5-149980428-C-T is Pathogenic according to our data. Variant chr5-149980428-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 4089.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr5-149980428-C-T is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SLC26A2NM_000112.4 linkc.835C>T p.Arg279Trp missense_variant Exon 3 of 3 ENST00000286298.5 NP_000103.2 P50443
SLC26A2XM_017009191.3 linkc.835C>T p.Arg279Trp missense_variant Exon 3 of 4 XP_016864680.1 P50443

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SLC26A2ENST00000286298.5 linkc.835C>T p.Arg279Trp missense_variant Exon 3 of 3 1 NM_000112.4 ENSP00000286298.4 P50443
SLC26A2ENST00000503336.1 linkc.372+2077C>T intron_variant Intron 1 of 1 3 ENSP00000426053.1 H0YA38

Frequencies

GnomAD3 genomes
AF:
0.00107
AC:
163
AN:
152092
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000193
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00256
Gnomad ASJ
AF:
0.00288
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000208
Gnomad FIN
AF:
0.000189
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00146
Gnomad OTH
AF:
0.00191
GnomAD3 exomes
AF:
0.000975
AC:
245
AN:
251240
Hom.:
0
AF XY:
0.000950
AC XY:
129
AN XY:
135782
show subpopulations
Gnomad AFR exome
AF:
0.000185
Gnomad AMR exome
AF:
0.00119
Gnomad ASJ exome
AF:
0.00199
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.0000327
Gnomad FIN exome
AF:
0.000139
Gnomad NFE exome
AF:
0.00150
Gnomad OTH exome
AF:
0.00114
GnomAD4 exome
AF:
0.00146
AC:
2129
AN:
1461850
Hom.:
5
Cov.:
33
AF XY:
0.00138
AC XY:
1007
AN XY:
727230
show subpopulations
Gnomad4 AFR exome
AF:
0.000239
Gnomad4 AMR exome
AF:
0.00114
Gnomad4 ASJ exome
AF:
0.00207
Gnomad4 EAS exome
AF:
0.0000252
Gnomad4 SAS exome
AF:
0.0000348
Gnomad4 FIN exome
AF:
0.000168
Gnomad4 NFE exome
AF:
0.00174
Gnomad4 OTH exome
AF:
0.00116
GnomAD4 genome
AF:
0.00107
AC:
163
AN:
152210
Hom.:
0
Cov.:
32
AF XY:
0.00112
AC XY:
83
AN XY:
74422
show subpopulations
Gnomad4 AFR
AF:
0.000193
Gnomad4 AMR
AF:
0.00255
Gnomad4 ASJ
AF:
0.00288
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.000208
Gnomad4 FIN
AF:
0.000189
Gnomad4 NFE
AF:
0.00146
Gnomad4 OTH
AF:
0.00189
Alfa
AF:
0.00149
Hom.:
0
Bravo
AF:
0.00122
TwinsUK
AF:
0.00243
AC:
9
ALSPAC
AF:
0.00182
AC:
7
ESP6500AA
AF:
0.000227
AC:
1
ESP6500EA
AF:
0.00163
AC:
14
ExAC
AF:
0.000799
AC:
97
Asia WGS
AF:
0.000577
AC:
2
AN:
3478
EpiCase
AF:
0.00125
EpiControl
AF:
0.00148

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:37Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Pathogenic:10
Jun 28, 2018
Eurofins Ntd Llc (ga)
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

May 06, 2022
GeneDx
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Most common pathogenic variant reported in the SLC26A2 gene among non-Finnish European individuals (Bonafe et al., 2014a); Reported as a mild disease-associated variant with phenotypic variability ranging from multiple epiphyseal dysplasia, when seen in the homozygous state, to the more severe diastrophic dysplasia, when seen in a compound heterozygous state (Bonafe et al., 2014a); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 10465113, 24598000, 20219950, 24458706, 26354092, 12193993, 20592910, 10482955, 22052783, 9342225, 11241838, 16642506, 27065010, 15316973, 29024831, 28726809, 26990548, 8931695, 30609409, 31028937, 30423444, 31980526, 32510848, 20301493, 15294877, 34426522, 31589614, 32333414, 33726816, 34064542, 33728303, 32633442, 34012376, 8571951, 23840040, 12525546, 33742171) -

Jun 17, 2021
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Feb 18, 2020
Blueprint Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Jan 28, 2020
Revvity Omics, Revvity
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Feb 09, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The SLC26A2 c.835C>T; p.Arg279Trp variant (rs104893915) is the second most frequently found SLC26A2 pathogenic variant. It has been described in the homozygous state in numerous individuals with autosomal recessive multiple epiphyseal dysplasia (rMED) with variable presentation including joint pain, hand/foot deformities, scoliosis, reduced stature, brachydactyly, abnormally shaped epiphyses and double layered patella (Ballhausen 2003, Barreda-Bonis 2018, Czarny-Ratajczak 2001, Huber 2001, Rossi 2001, Superti-Furga 1999). It has also been observed in the compound heterozygous state in patients with rMED, diastrophic dysplasia, atelosteogenesis, and in a patient with intermediate phenotype of diastrophic dysplasia/atelosteogenesis (Barreda-Bonis 2018, Hastbacka 1996, Macias-Gomez 2004, Rossi 1996). It is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 4089), and is observed in the general population at an overall frequency of 0.098% (271/276946 alleles) in the Genome Aggregation Database. Additionally, functional in vitro studies of the variant protein demonstrate reduced protein expression and sulfate transport function, but proper glycosylation and plasma membrane targeting when compared to wild type protein (Karniski 2004). Based on available information, this variant is considered pathogenic. REFERENCES Ballhausen D et al. Recessive multiple epiphyseal dysplasia (rMED): phenotype delineation in eighteen homozygotes for DTDST mutation R279W. J Med Genet 2003; 40:65. Barreda-Bonis A et al. Multiple SLC26A2 mutations occurring in a three-generational family. Eur J Med Genet. 2018 Jan;61(1):24-28. Czarny-Ratajczak M et al. A mutation in COL9A1 causes multiple epiphyseal dysplasia: further evidence for locus heterogeneity. Am J Hum Genet 2001; 69:669-80. Hastbacka J et al. Atelosteogenesis type II is caused by mutations in the diastrophic dysplasia sulfate-transporter gene (DTDST): evidence for a phenotypic series involving three chondrodysplasias. Am J Hum Genet 1996; 58(2):255-262. Huber C et al. Sulphate transporter gene mutations in apparently isolated club foot. J Med Genet 2001; 38:191-3. Karniski LP et al. Functional expression and cellular distribution of diastrophic dysplasia sulfate transporter (DTDST) gene mutations in HEK cells. Hum Mol Genet 2004; 13(19):2165-2171. Macias-Gomez NM et al. Diastrophic dysplasia and atelosteogenesis type II as expression of compound heterozygosis: first report of a Mexican patient and genotype-phenotype correlation. Am J Med Genet A 2004; 129A(2):190-192. Rossi A et al. Mutations in the diastrophic dysplasia sulfate transporter (DTDST) gene (SLC26A2): 22 novel mutations, mutation review, associated skeletal phenotypes, and diagnostic relevance. Hum Mutat 2001; 17(3):159-171. Rossi A et al. Phenotypic and genotypic overlap between atelosteogenesis type 2 and diastrophic dysplasia. Hum Genet 1996; 98(6):657-661. Superti-Furga A et al. Recessively inherited multiple epiphyseal dysplasia with normal stature, club foot, and double layered patella caused by a DTDST mutation. J Med Genet 1999; 36:621-624. -

Oct 01, 2024
CeGaT Center for Human Genetics Tuebingen
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

SLC26A2: PM3:Very Strong, PM2, PS3:Supporting -

Multiple epiphyseal dysplasia type 4 Pathogenic:8
Jul 06, 2022
Baylor Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Aug 30, 2004
OMIM
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: literature only

- -

-
Kasturba Medical College, Manipal, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

A known missense variant, c.835C>T (ClinVar variation ID: 4089; Maeda K et al., 2006) in exon 3 of SLC26A2 gene was observed in homozygous state in proband. On segregation, the variant was observed in heterozygous state in her mother and father. This variant is observed in gnomAD (v4.1.0) population database with an allele frequency of 0.001420 (het count: 2292, hom count: 5) and in 3 individuals in heterozygous state in our in-house data of 3455 exomes -

Jul 06, 2020
Equipe Genetique des Anomalies du Developpement, Université de Bourgogne
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Oct 11, 2017
Institute of Human Genetics, University of Leipzig Medical Center
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Feb 01, 2024
Laboratory of Medical Genetics, National & Kapodistrian University of Athens
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: curation

- -

Nov 18, 2019
Myriad Genetics, Inc.
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

NM_000112.3(SLC26A2):c.835C>T(R279W) is classified as pathogenic and is associated with recessive multiple epiphyseal dysplasia. Sources cited for classification include the following: PMID 8571951, 11565064, 11303514, 12525546, and 9342225. Classification of NM_000112.3(SLC26A2):c.835C>T(R279W) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. -

Jun 13, 2018
Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant is an established disease-causing mutation that has been reported as pathogenic by multiple clinical diagnostic laboratories in ClinVar (Variation ID# 4089). This variant has been reported in the homozygous state in individuals with multiple epiphyseal dysplasia (PMID 20301483, 12525546). This variant is present as a heterozygous change in the gnomAD population database at a frequency of 0.001% (271/276946) and thus is presumed to be rare. It affects a highly conserved amino acid (up to Tetraodon, considering 12 species) and is predicted by multiple in silico tools to have a deleterious effect on protein function. Based on the available evidence, the c.835C>T (p.Arg279Trp) variant is classified as pathogenic. -

Diastrophic dysplasia Pathogenic:5Other:1
Aug 30, 2004
OMIM
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: literature only

- -

Jul 06, 2022
Baylor Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
GeneReviews
Significance: not provided
Review Status: no classification provided
Collection Method: literature only

- -

Nov 18, 2019
Myriad Genetics, Inc.
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

NM_000112.3(SLC26A2):c.835C>T(R279W) is classified as pathogenic and is associated with recessive multiple epiphyseal dysplasia. Sources cited for classification include the following: PMID 8571951, 11565064, 11303514, 12525546, and 9342225. Classification of NM_000112.3(SLC26A2):c.835C>T(R279W) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. -

Dec 02, 2022
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

ACMG classification criteria: PS3 supporting, PM3 very strong, PP3 supporting -

Jan 31, 2018
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The p.Arg279Trp (NM_000112.3 c.835C>T) variant in SLC26A2 has been reported in m any homozygous and compound heterozygous individuals with a range of diseases wi thin the diastrophic dysplasia spectrum, and has generally been associated with milder multiple epiphseal dysplasia when it is homozygous or compound heterozygo us with another mild variant, and with more severe diastrophic dysplasia or atel osteogenesis type 2 when it is compound heterozygous with a severe SLC26A2 varia nt (Rossi 1996, Hastaback 1996, Superti-Furga 1999, Huber 2001, Czarny-Ratajczak 2001, Ballhausen 2003, Macias-Gomze 2004, Dwyer 2010, Barbosa 2011, Mattos 2014 , Makitie 2015). This variant has also been reported in ClinVar (Variation ID#40 89) as pathogenic by multiple laboratories. In vitro functional studies provide support that the variant impacts the protein (Karniski 2004, and Heneghan 2010). This variant has been identified in 0.217% (22/10,138) of Ashkenazi Jewish chro mosomes by the Genome Aggregation Database (gnomAD, http://gnomAD.broadinstitute .org; dbSNP rs104893915). Although this variant has been seen in the general pop ulation, its frequency is low enough to be consistent with a recessive carrier f requency. In summary, this variant meets criteria to be classified as pathogenic for diastrophic dysplasia in an autosomal recessive manner based upon its biall elic occurrence in individuals with this disease and the predicted impact on the protein. -

Achondrogenesis, type IB Pathogenic:3
Sep 16, 2020
Natera, Inc.
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Nov 18, 2019
Myriad Genetics, Inc.
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

NM_000112.3(SLC26A2):c.835C>T(R279W) is classified as pathogenic and is associated with recessive multiple epiphyseal dysplasia. Sources cited for classification include the following: PMID 8571951, 11565064, 11303514, 12525546, and 9342225. Classification of NM_000112.3(SLC26A2):c.835C>T(R279W) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. -

Mar 30, 2024
Baylor Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Diastrophic dysplasia;C0265274:Achondrogenesis, type IB;C1847593:Multiple epiphyseal dysplasia type 4;C1850554:Atelosteogenesis type II Pathogenic:3
May 24, 2024
Fulgent Genetics, Fulgent Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Jan 27, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 279 of the SLC26A2 protein (p.Arg279Trp). This variant is present in population databases (rs104893915, gnomAD 0.2%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individuals with SLC26A2-related disease (PMID: 8571951, 9342225, 10465113, 10482955, 16642506, 21077202, 22052783, 23840040, 27065010). ClinVar contains an entry for this variant (Variation ID: 4089). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt SLC26A2 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects SLC26A2 function (PMID: 15294877, 20219950). For these reasons, this variant has been classified as Pathogenic. -

-
Juno Genomics, Hangzhou Juno Genomics, Inc
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

PM2_Supporting+PP3_Moderate+PM3_VeryStrong+PP4 -

Atelosteogenesis type II Pathogenic:2
Aug 30, 2004
OMIM
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: literature only

- -

Jul 06, 2022
Baylor Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

SLC26A2-related disorder Pathogenic:2
Aug 19, 2016
Illumina Laboratory Services, Illumina
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The SLC26A2 c.835C>T (p.Arg279Trp) missense variant is well-described in the literature as the most common pathogenic variant in sulfate transporter-related osteochondrodysplasia outside of Finland, accounting for 45% of disease alleles (Bonafé et al. 2013). The p.Arg279Trp variant has been reported in at least nine studies in which it is found in a total of 43 patients with SLC26A2-related disorders including 25 in a homozygous state, 12 in a compound heterozygous state, and six in a heterozygous state where a second variant was not detected (Hästbacka et al. 1996; Rossi et al. 1996; Superti-Furga et al. 1999; Czarny-Ratajczak et al. 2001; Huber et al. 2001; Ballhausen et al. 2003; Macías-Gómez et al. 2004; Mattos et al. 2014; Mäkitie et al. 2015). The p.Arg279Trp variant was absent from 120 controls, but is reported at a frequency of 0.00432 in the admixed American population of the 1000 Genomes Project. This allele frequency is high but may be explained by a milder phenotypic presentation. Functional studies in Xenopus oocytes demonstrated that the p.Arg279Trp variant results in reductions of 70% to 80% of the uptake of both sulfate and oxalate compared to wild type, while the surface abundance of the variant protein was similar to wild type levels (Heneghan et al. 2010). The p.Arg279Trp variant is generally considered a mild pathogenic variant. Individuals who are homozygous for the p.Arg279Trp variant have a mild phenotype and are generally diagnosed with multiple epiphyseal dysplasia, but may have some features of diastrophic dysplasia. Some homozygous individuals may also be asymptomatic and remain undiagnosed. A range of phenotypes is seen in individuals who are compound heterozygous for the p.Arg279Trp variant and another missense variant or the well-described Finnish variant in the 5' UTR. The majority of these cases fall into the diastrophic dysplasia category, but can also be more severe or milder. Individuals who are compound heterozygous for the p.Arg279Trp variant and a premature stop-gained variant usually present with atelosteogenesis or sometimes with diastrophic dysplasia. Thus far, the p.Arg279Trp variant has not been associated with any cases of achondrogenesis, which is the most severe disease in the spectrum. Based on the collective evidence, the p.Arg279Trp is classified as pathogenic for SLC26A2-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. -

Sep 10, 2024
PreventionGenetics, part of Exact Sciences
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: clinical testing

The SLC26A2 c.835C>T variant is predicted to result in the amino acid substitution p.Arg279Trp. This variant has been reported to be causative for diastrophic dysplasia (Hastbacka et al. 1999. PubMed ID: 10482955; Hastbacka et al. 1996. PubMed ID: 8571951), for mild recessive multiple epiphyseal dysplasia (Lacassie et al. 2011. PubMed ID: 22052783), and for diastrophic dysplasia/multiple epiphyseal dysplasia (Zechi-Ceide et al. 2013. PubMed ID: 23840040). This variant is classified as pathogenic by multiple independent submitters to the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/4089). Given the evidence, we interpret c.835C>T (p.Arg279Trp) as pathogenic. -

Inborn genetic diseases Pathogenic:1
Jun 09, 2023
Ambry Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The c.835C>T (p.R279W) alteration is located in exon 3 (coding exon 2) of the SLC26A2 gene. This alteration results from a C to T substitution at nucleotide position 835, causing the arginine (R) at amino acid position 279 to be replaced by a tryptophan (W). Based on data from gnomAD, the T allele has an overall frequency of 0.096% (271/282628) total alleles studied. The highest observed frequency was 0.222% (23/10358) of Ashkenazi Jewish alleles. The p.R279W alteration has been observed homozygous or compound heterozygous in individuals presenting with various disorders including multiple epiphyseal dysplasia (rMED), diastrophic dysplasia (DTD), and atelosteogenesis type II. This alteration is the most common in the European, Non-Finnish population (Superti-Furga, 1999; Rossi, 2001). Patients who are homozygous for this alteration typically have a clinical diagnosis of multiple epiphyseal dysplasia (Ballhausen, 2003) Other patients in which the p.R279W alteration occurs in trans with a second mutation can have atelosteogenesis type II (Hastback, 1996), diastrophic dysplasia (Rossi, 2001), or intermediate syndromes involving various features of these disorders (Zechi-Ceide, 2013; Maeda, 2006). This amino acid position is highly conserved in available vertebrate species. The p.R279 amino acid is located in the sulfate transporter family protein domain (Rossi, 2001). Functional analysis demonstrated that the p.R279W alteration decreased protein function (~45% of wildtype) (Karniski, 2004). This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. -

Sulfate transporter-related osteochondrodysplasia Pathogenic:1
Jul 21, 2016
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: The SLC26A2 c.835C>T (p.Arg279Trp) variant involves the alteration of a conserved nucleotide resulting in a replacement of a large size and basic Arginine (R) with a large size and aromatic Tryptophan (W) located in the sulphate transferase domain. 4/4 in silico tools predict a damaging outcome for this substitution. This variant was found in 97/121378 control chromosomes at a frequency of 0.0007992, which does not exceed the estimated maximal expected allele frequency of a pathogenic SLC26A2 variant (0.002958). It was reported in several non-lethal SLC26A2-related dysplasia patients in either homozygosity or in compound heterozygosity with other pathogenic mutations indicating pathogenicity. Additionally, independent functional studies demonstrated the variant to impair sulphate and oxalate transport activity of SLC26A2 further supporting a deleterious impact. In addition, the variant is known as one of the most common pathogenic SLC26A2 (GeneReviews). Considering all evidence, the variant was classified as Pathogenic. -

3MC syndrome 2 Pathogenic:1
Nov 18, 2019
Myriad Genetics, Inc.
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

NM_000112.3(SLC26A2):c.835C>T(R279W) is classified as pathogenic and is associated with recessive multiple epiphyseal dysplasia. Sources cited for classification include the following: PMID 8571951, 11565064, 11303514, 12525546, and 9342225. Classification of NM_000112.3(SLC26A2):c.835C>T(R279W) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. -

Connective tissue disorder Pathogenic:1
Aug 18, 2021
Genome Diagnostics Laboratory, The Hospital for Sick Children
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.38
BayesDel_addAF
Pathogenic
0.17
D
BayesDel_noAF
Pathogenic
0.47
CADD
Pathogenic
29
DANN
Pathogenic
1.0
DEOGEN2
Pathogenic
0.88
D
Eigen
Pathogenic
0.78
Eigen_PC
Pathogenic
0.69
FATHMM_MKL
Uncertain
0.88
D
LIST_S2
Uncertain
0.97
D
M_CAP
Pathogenic
0.32
D
MetaRNN
Uncertain
0.55
D
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Pathogenic
3.5
H
PrimateAI
Uncertain
0.61
T
PROVEAN
Pathogenic
-7.4
D
REVEL
Pathogenic
0.92
Sift
Pathogenic
0.0
D
Sift4G
Pathogenic
0.0
D
Polyphen
1.0
D
Vest4
0.90
MVP
0.99
MPC
0.33
ClinPred
0.49
T
GERP RS
5.1
Varity_R
0.96
gMVP
0.89

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs104893915; hg19: chr5-149359991; COSMIC: COSV99640198; COSMIC: COSV99640198; API